Liftstream is an executive search recruitment company in the life sciences sector
Complix, a biopharmaceutical company focused on developing a pipeline of transformative protein therapeutics, called Alphabodies™, mainly focused on oncology and autoimmune diseases, today announced the appointment of Hans Schikan as Chairman of its Board of Directors.
On January 10th 2013, BioMarin announced it had acquired the privately held US biotechnology company Zacharon Pharmaceuticals. Zacharon develops small molecules targeting pathways of glycan and glycolipid metabolism. BioMarin has purchased 100% of Zacahron’s shares with a $10m upfront payment combined with regular clinical, regulatory and commercial milestone payments. BioMarin operates in the Rare Disease space where it currently has 4 marketed products and now employs over 1000 personnel worldwide.
This year has been a tumultuous year for the rare diseases market with a number of significant news stories revolving around M&A rumours, regulatory approvals, IPO’s, investments and partnering agreements. Liftstream takes a look at these events: